Chronic Pulmonary Infections Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GSK

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Pulmonary Infections pipeline constitutes 10+ key companies continuously working towards developing 10+ Chronic Pulmonary Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Chronic Pulmonary Infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Pulmonary Infections Market.

 

The Chronic Pulmonary Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Chronic Pulmonary Infections Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Pulmonary Infections treatment therapies with a considerable amount of success over the years. 

• Chronic Pulmonary Infections companies working in the treatment market are Armata Pharmaceuticals, BiomX, Inc., Respirion Pharmaceuticals, Chiesi Farmaceutici S.p.A., Incyte Corporation, American Health Research, Temple University, Altesa Biosciences, Genentech, Inc., and others, are developing therapies for the Chronic Pulmonary Infections treatment 

• Emerging Chronic Pulmonary Infections therapies in the different phases of clinical trials are- AP-PA02, BX004-A, RSP-1502, CHF6001, itacitinib, Guafenesin tablets, Quercetin, Vapendavir, GDC-6599, and others are expected to have a significant impact on the Chronic Pulmonary Infections market in the coming years.   

• In May 2024, Insmed’s stock price surged over 100% following the announcement that their leading pipeline candidate, brensocatib, achieved success in a Phase III trial. The much-anticipated ASPEN trial (NCT04594369) was an international, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.

• In May 2024, Pfizer Inc. (NYSE: PFE) has released extended follow-up results from the Phase 3 CROWN trial, which compared LORBRENA® (lorlatinib), a third-generation ALK inhibitor, to XALKORI® (crizotinib) in patients with previously untreated, ALK-positive advanced non-small cell lung cancer (NSCLC). After a median follow-up of five years, the median progression-free survival (PFS) for LORBRENA, as assessed by investigators, was not reached. The observed Hazard Ratio (HR) was 0.19 (95% Confidence Interval [CI], 0.13-0.27), indicating an 81% reduction in disease progression or death compared to XALKORI.

 

Chronic Pulmonary Infections Overview

Chronic pulmonary infections refer to persistent or long-lasting infections affecting the respiratory system, particularly the lungs. These infections can be caused by various pathogens such as bacteria, viruses, fungi, or parasites. Chronic pulmonary infections are characterized by their prolonged duration and can lead to significant respiratory symptoms and complications if not properly managed.

 

Get a Free Sample PDF Report to know more about Chronic Pulmonary Infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-pulmonary-infections-pipeline-insight

 

Emerging Chronic Pulmonary Infections Drugs Under Different Phases of Clinical Development Include:

• AP-PA02: Armata Pharmaceuticals

• BX004-A: BiomX, Inc.

• RSP-1502: Respirion Pharmaceuticals

• CHF6001: Chiesi Farmaceutici S.p.A.

• itacitinib: Incyte Corporation

• Guafenesin tablets: American Health Research

• Quercetin: Temple University

• Vapendavir: Altesa Biosciences

• GDC-6599: Genentech, Inc.

 

Chronic Pulmonary Infections Route of Administration

Chronic Pulmonary Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

 

Chronic Pulmonary Infections Molecule Type

Chronic Pulmonary Infections Products have been categorized under various Molecule types, such as

• Monoclonal antibody

• Small molecule

• Peptide

 

Chronic Pulmonary Infections Pipeline Therapeutics Assessment

• Chronic Pulmonary Infections Assessment by Product Type

• Chronic Pulmonary Infections By Stage and Product Type

• Chronic Pulmonary Infections Assessment by Route of Administration

• Chronic Pulmonary Infections By Stage and Route of Administration

• Chronic Pulmonary Infections Assessment by Molecule Type

• Chronic Pulmonary Infections by Stage and Molecule Type

 

DelveInsight's Chronic Pulmonary Infections Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Chronic Pulmonary Infections product details are provided in the report. Download the Chronic Pulmonary Infections pipeline report to learn more about the emerging Chronic Pulmonary Infections therapies

 

Some of the key companies in the Chronic Pulmonary Infections Therapeutics Market include:

Key companies developing therapies for Chronic Pulmonary Infections are - Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim International Gmbh, Teva Pharmaceutical Industries Ltd, Sanofi, Mylan Pharmaceuticals, Sun Pharmaceutical, and others.

 

Chronic Pulmonary Infections Pipeline Analysis:

The Chronic Pulmonary Infections pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Pulmonary Infections with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Pulmonary Infections Treatment.

• Chronic Pulmonary Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Pulmonary Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Pulmonary Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Pulmonary Infections drugs and therapies

 

Chronic Pulmonary Infections Pipeline Market Drivers

• Increasing Prevalence, Unmet Medical Needs, Advancements in Biotechnology, Government Initiatives, Growing Healthcare Expenditure, are some of the important factors that are fueling the Chronic Pulmonary Infections Market.

 

Chronic Pulmonary Infections Pipeline Market Barriers

• However, Complexity in Diagnosis, Regulatory Hurdles, High Development Costs, Antibiotic Resistance, Limited Awareness, and other factors are creating obstacles in the Chronic Pulmonary Infections Market growth.

 

Scope of Chronic Pulmonary Infections Pipeline Drug Insight    

• Coverage: Global

• Key Chronic Pulmonary Infections Companies: Armata Pharmaceuticals, BiomX, Inc., Respirion Pharmaceuticals, Chiesi Farmaceutici S.p.A., Incyte Corporation, American Health Research, Temple University, Altesa Biosciences, Genentech, Inc., and others

• Key Chronic Pulmonary Infections Therapies: AP-PA02, BX004-A, RSP-1502, CHF6001, itacitinib, Guafenesin tablets, Quercetin, Vapendavir, GDC-6599, and others

• Chronic Pulmonary Infections Therapeutic Assessment: Chronic Pulmonary Infections current marketed and Chronic Pulmonary Infections emerging therapies

• Chronic Pulmonary Infections Market Dynamics: Chronic Pulmonary Infections market drivers and Chronic Pulmonary Infections market barriers 

 

Request for Sample PDF Report for Chronic Pulmonary Infections Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Pulmonary Infections Report Introduction

2. Chronic Pulmonary Infections Executive Summary

3. Chronic Pulmonary Infections Overview

4. Chronic Pulmonary Infections- Analytical Perspective In-depth Commercial Assessment

5. Chronic Pulmonary Infections Pipeline Therapeutics

6. Chronic Pulmonary Infections Late Stage Products (Phase II/III)

7. Chronic Pulmonary Infections Mid Stage Products (Phase II)

8. Chronic Pulmonary Infections Early Stage Products (Phase I)

9. Chronic Pulmonary Infections Preclinical Stage Products

10. Chronic Pulmonary Infections Therapeutics Assessment

11. Chronic Pulmonary Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Pulmonary Infections Key Companies

14. Chronic Pulmonary Infections Key Products

15. Chronic Pulmonary Infections Unmet Needs

16 . Chronic Pulmonary Infections Market Drivers and Barriers

17. Chronic Pulmonary Infections Future Perspectives and Conclusion

18. Chronic Pulmonary Infections Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Massage by Design Wins the 2024 Quality Business Award for The Best Massage Therapist in West Chicago, Illinois

A therapeutic chair massage

West Chicago, IL - October 1, 2024 - Massage by Design has received the 2024 Quality Business Award for The Best Corporate and Event Chair Massage in West Chicago, Illinois. This accolade acknowledges Massage by Design for its exceptional customer service, high-quality services, and overall business performance.

The Quality Business Awards annually acknowledges businesses exhibiting excellence within their industry. Selections are determined by taking into account their reputation, feedback from customers, and overall performance within their respective industries.

Massage by Design is a leading massage therapist in West Chicago, Illinois. Massage by Design is a nationwide company that provides calming, safe, and therapeutic chair massages for workplaces and special events. Massage by Design makes it easy for companies and event organizers to book qualified chair massage therapists for corporate massage, marketing events, conferences, workplace massage, expos, and trade shows. Koko Klipper, the owner and CEO of Massage by Design, has a background in business management and has been a Licensed Massage Therapist from Utah for over eighteen years. The rest of the Massage by Design team consists of Senior Event Coordinator Sarah Figueroa, Event Coordinator Brooklyn Tanner, Salesforce Leader and Developer Nicole Simon, Administrative Coordinator Paula Fullmer, Bookkeepers Cheryl Nichols and Jessica Nichols, Chief Marketing Officer “Chante” Wolf, and many licensed, certified and insured massage therapists. Massage by Design is certified as a women's business enterprise by the Women’s Business Enterprise National Council. Massage by Design are proud to serve West Chicago and many other cities across the United States.

Chair massage was first introduced to the United States in the late 1960s and it has many physical and psychological benefits. Some of the many benefits of chair massage include: stress relief; improved immunity; pain reduction; increased productivity; reduced fatigue; increased office morale; and increased employee retention. Massage by Design makes it easy for businesses and event organizers to book chair massages for their employees and event attendees. Their mobile team of chair massage therapists will bring value to any workplace or event. Businesses and event organizers can easily benefit from the chair massage services provided by Massage by Design.

When the time came to choose this year's recipient, Massage by Design emerged as a noteworthy company in the massage therapy sector. Their professional and reliable team is well-regarded within the West Chicago community, and positive reviews of Massage by Design are abundant. Here are a few of the numerous positive testimonials penned by satisfied customers who were thoroughly impressed with the communication and chair massage services offered by Massage by Design. “An amazing team and amazing experience. We got a break from the day and treated to a massage. The team was so mindful about any aches or pains and continued to check on me throughout the massage.” “Not one to normally leave reviews, but wow! Great massage!” “I have been working with Koko for years on many client conferences and events” “Excellent massage! So kind and accommodating during a women's conference! Definitely recommend using them!!” The entire Massage by Design team consistently exceed expectations by delivering mobile chair massage services for each customer.

The Quality Business Awards recognizes businesses achieving an average quality score of 95% or higher throughout the preceding year. To be eligible, a business must garner outstanding customer reviews from at least three different platforms. Those upholding sterling reputations and track records over multiple years with minimal complaints receive high scores. Moreover, businesses that consistently engage with and respond to customer feedback are held in high esteem. Additionally, adherence to integrity, community involvement, and proactive efforts to reduce environmental impact are important criteria. Receiving a Quality Business Award shows a dedication to delivering superior products and exceptional customer service.

For more information about Massage by Design, please visit the company's website at [Unwind at Work: Premier Chicago Corporate Chair Massage Services (massagebydesign.net)].

Contact:

Quality Business Awards

support@qualitybusinessawards.com

Media Contact
Company Name: Massage by Design
Email:Send Email
Country: United States
Website: https://massagebydesign.net/

Hemophilia B Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA and ROA by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemophilia B pipeline constitutes 15+ key companies continuously working towards developing 20+ Hemophilia B treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Hemophilia B Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia B Market.

 

The Hemophilia B Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Hemophilia B Pipeline Report 

• Companies across the globe are diligently working toward developing novel Hemophilia B treatment therapies with a considerable amount of success over the years. Hemophilia B Key players such as - Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others are developing therapies for the Hemophilia B treatment 

• Hemophilia B Emerging therapies such as - BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran, PF-06, and others are expected to have a significant impact on the Hemophilia B market in the coming years. 

• In July 2024, CSL Behring has reported the treatment of two patients with HEMGENIX (etranacogene dezaparvovec) gene therapy for haemophilia B, a hereditary bleeding condition. The treatments were administered at haemophilia centres in France. HEMGENIX underwent extensive clinical development led by UniQure, with CSL Behring assuming sponsorship of the trials after acquiring global commercial rights to the therapy.

 

Hemophilia B Overview

Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient blood protein levels called factor IX. Hemophilia B, also known as factor IX deficiency or Christmas disease, is the second most common type of hemophilia. Factor IX is a clotting factor. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.

 

To know more about the Hemophilia B pipeline report, click here: 

https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight

 

Hemophilia B Pipeline Therapies along with Key Players:

• BBM-H901: Belief Biomed

• ISU304: ISU ABXIS

• TU7710: TiumBio

• BE-101: Be Biopharma

• REGV131: Regeneron Pharmaceuticals

• PF-06838435: Pfizer

• ANB-002: Biocad

• AAV5-hFIXco-Padua: CSL Behring

• VGB-R04: Shanghai Vitalgen BioPharma

• AskBio009: Baxalta

• AMA005: Amarna therapeutics

• CB 2679d-GT: Catalyst Biosciences

• FLT180a: Freeline Therapeutics

• BBM-H901: Belief BioMed

• SerpinPC: Centessa Pharmaceuticals

• Concizumab: Novo Nordisk

• Fitusiran: Sanofi

• PF-06741086: Pfizer

 

Hemophilia B Pipeline Therapeutics Assessment

The  Hemophilia B Pipeline report proffers an integral view of the Hemophilia B emerging novel therapies segmented by Stage, Product Type,  Molecule Type,  Mechanism of Action, and Route of Administration. 

 

Hemophilia B Pipeline Clinical Phases:

DelveInsight’s Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates 

 

Further Hemophilia B product details are provided in the report. Download the Hemophilia B pipeline report to learn more about the emerging Hemophilia B therapies

 

Some of the key companies in the Hemophilia B Therapeutics Market include:

Key companies developing therapies for Hemophilia B treatment are - Aptevo, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, GC Pharma, Kaifeng Pharmaceutical, KM Biologics, LFB, Novo Nordisk, Pfizer, Octapharma, Roche, Sanofi, SinoCelltech, Spark Therapeutics, Takeda, UniQure, and others.

 

 

Hemophilia B Pipeline Analysis:

The report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Hemophilia B treatment with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B Treatment.

• Hemophilia B key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Hemophilia B Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia B market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Hemophilia B Pipeline Market Drivers

• Increasing prevalence of Hemophilia B disease

• Increasing R&D on identifying new therapeutic agents 

 

Hemophilia B Pipeline Market Barriers

• High cost of Hemophilia B treatment 

 

Download the Hemophilia B pipeline report to learn more about the emerging Hemophilia B therapies

 

Scope of Hemophilia B Pipeline Drug Insight    

• Coverage: Global

• Key Hemophilia B Companies: Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others

• Key Hemophilia B Therapies: BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others

• Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies

• Hemophilia B Market Dynamics:  Hemophilia B market drivers and Hemophilia B market barriers 

 

Get a Free Sample PDF Report to know more about Hemophilia B Pipeline Assessment

 

Table of Contents

1	Hemophilia B Report Introduction
2	Hemophilia B Executive Summary
3	Hemophilia B Overview
4	Hemophilia B- Analytical Perspective In-depth Commercial Assessment
5	Hemophilia B Pipeline Therapeutics
6	Hemophilia B Late Stage Products (Phase II/III)
7	Hemophilia B Mid Stage Products (Phase II)
8	Hemophilia B Early Stage Products (Phase I)
9	Hemophilia B Preclinical Stage Products
10	Hemophilia B Therapeutics Assessment
11	Hemophilia B Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Hemophilia B Key Companies
14	Hemophilia B Key Products
15	Hemophilia B Unmet Needs
16	Hemophilia B Market Drivers and Barriers
17	Hemophilia B Future Perspectives and Conclusion
18	Hemophilia B Analyst Views
19	Appendix
20	About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas

Las Vega (Nevada), United States //— As per DelveInsight's assessment, globally, Pompe Disease pipeline constitutes 15+ key companies continuously working towards developing 20+ Pompe Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Pompe Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.

 

The Pompe Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Pompe Disease Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Pompe Disease treatment therapies with a considerable amount of success over the years. Pompe Disease Key players such as - Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others, are developing therapies for the Pompe Disease treatment 

• Pompe Disease Emerging therapies such as - ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others are expected to have a significant impact on the Pompe Disease market in the coming years. 

• In May 2024, Shionogi & Co., Ltd. (Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have announced the completion of an exclusive global licensing agreement for MZE001. MZE001 is an investigational oral glycogen synthase 1 (GYS1) inhibitor designed to address Pompe disease by reducing the buildup of disease-causing glycogen.

• In November 2023, Aro Biotherapeutics, a clinical-stage biotech company, has secured $41.5 million in a Series B funding round to further develop its lead candidate, ABX1100, for the treatment of Pompe disease. The round was led by Cowen Healthcare Investments, with participation from Series A investors including Northpond Ventures, Johnson & Johnson Innovation – JJDC, BVF Partners, and HealthCap.

 

Pompe Disease Overview

Pompe disease belongs to the 'lysosomal storage disorders' (LSDs) group of diseases. Within the cells, lysosomes are tiny compartments where all sorts of substances are recycled. By the action of digestive enzymes, the compounds are degraded. There are currently more than 50 different LSDs that are considered to be caused by the deficiency of one of these enzymes.

 

Get a Free Sample PDF Report to know more about Pompe Disease Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight

 

Route of Administration

Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

 

Pompe Disease Pipeline Therapeutics Assessment

• Pompe Disease Assessment by Product Type

• Pompe Disease By Stage and Product Type

• Pompe Disease Assessment by Route of Administration

• Pompe Disease By Stage and Route of Administration

• Pompe Disease Assessment by Molecule Type

• Pompe Disease by Stage and Molecule Type

 

DelveInsight's Pompe Disease Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Some of the key companies in the Pompe Disease Therapeutics Market include:

Key companies developing therapies for Pompe Disease are - Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics, and others.

 

Emerging Pompe Disease Drugs Under Different Phases of Clinical Development Include:

• ACTUS-101: Asklepios Biopharmaceutical

• GC301: GeneCradle Inc

• zocaglusagene nuzaparvovec: Astellas Gene Therapies

• AT2221: Amicus Therapeutics

• M 021: M6P Therapeutics

• GYS1 Knockdown Oligonucleotide: Entrada Therapeutics

• MZE 001: Maze Therapeutics

• AT845: Astellas Gene Therapies

• AAV2/8LSPhGAA: Asklepios Biopharmaceutical

• SPK-3006: Spark Therapeutics

• Cipaglucosidase alfa: Amicus Therapeutics

 

Download Sample PDF Report to know more about Pompe Disease drugs and therapies

 

Pompe Disease Pipeline Analysis:

The Pompe Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.

• Pompe Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pompe Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Pompe Disease product details are provided in the report. Download the Pompe Disease pipeline report to learn more about the emerging Pompe Disease therapies

 

Pompe Disease Pipeline Market Drivers

• Improving Healthcare Infrastructure

• Demand for New and Effective Drugs

• Increasing research and development in the gene therapy and enzyme replacement therapy areas

 

Pompe Disease Pipeline Market Barriers

• Lack Of Cost-Effective Treatment

 

Scope of Pompe Disease Pipeline Drug Insight    

• Coverage: Global

• Key Pompe Disease Companies: Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others

• Key Pompe Disease Therapies: ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others

• Pompe Disease Therapeutic Assessment: Pompe Disease current marketed and Pompe Disease emerging therapies

• Pompe Disease Market Dynamics: Pompe Disease market drivers and Pompe Disease market barriers 

 

Request for Sample PDF Report for Pompe Disease Pipeline Assessment and clinical trials

 

Table of Contents

1	Pompe Disease Report Introduction
2	Pompe Disease Executive Summary
3	Pompe Disease Overview
4	Pompe Disease- Analytical Perspective In-depth Commercial Assessment
5	Pompe Disease Pipeline Therapeutics
6	Pompe Disease Late Stage Products (Phase II/III)
7	Pompe Disease Mid Stage Products (Phase II)
8	Pompe Disease Early Stage Products (Phase I)
9	Pompe Disease Preclinical Stage Products
10	Pompe Disease Therapeutics Assessment
11	Pompe Disease Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Pompe Disease Key Companies
14	Pompe Disease Key Products
15	Pompe Disease Unmet Needs
16	Pompe Disease Market Drivers and Barriers
17	Pompe Disease Future Perspectives and Conclusion
18	Pompe Disease Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Daylight Saving Time by David W. Berner is an Empowering Memoir about the Power of Growing Older

Filled with deeply personal and candid observations, insights and revelations on the act of aging, David W. Berner's Daylight Saving Time offers a refreshing outlook on the grand adventure of life and the passage of time.

David W. Berner is an award-winning journalist, broadcaster, author, and teacher.

He is the best-selling, award-winning author of fiction, creative nonfiction, memoir, short stories, and poetry. His work includes the novels A Well-Respected Man, The Islander, Night Radio, Sandman, and Rainbow Man, and the nonfiction books Accidental Lessons, Any Road Will Take You There, Walks with Sam, The Consequence of Stars, and Daylight Saving Time. He has won an Eric Hoffer Book Award, Book Excellence Award, NYC Big Book Award, National Association of Independent Writers and Editors Award for Literary Fiction, and the Book of the Year Award from the Chicago Writers Association. He's also been recognized by the Paris Book Festival, the London Book Festival, The Society of Midland Authors, the Hawthorne Prize, the Royal Dragonfly Awards, and the Readers' Choice Awards.

David has been honored as the Writer-in-Residence at the Jack Kerouac Project in Orlando, FL and at the Ernest Hemingway Birthplace Home and Museum in Oak Park, IL.

David is a retired associate-professor at Columbia College Chicago, a long-time Chicago broadcast journalist, and now teaches writing at Gotham Writers Workshop of New York City. He writes a regular blog on writing, music, and the arts at The Writer Shed on Medium and personal essays at The Abundance on Substack. 

This one-on-one interview shares David W. Berner’s background and experience writing Daylight Saving Time: The Power of Growing Older.

Tell us about Daylight Saving Time: The Power of Growing Older.

When we are young, we think little about growing old.

But time soon catches up with us: the first gray hair, a buckling knee, the purchase of reading glasses, or when a heart attack at the age of 56 rattles your world and reminds you that none of us get out of here alive.

Daylight Saving Time is a meditative and intimate personal narrative on the act of aging where I discover how to accept and revel in the present, when the days that remain are fewer than those that have passed, offering a path for celebrating life's final chapters.

Through the lessons of seasonal change, the natural world, literature, and spirituality, I offer readers a kind of instruction book on the art of growing older, challenging our society to accept aging and its transformative power. I hope I can share a guiding philosophy on how to discover joy in the time we have left and nourishment in life's remaining seasons.

What inspired you to write Daylight Saving Time: The Power of Growing Older?

I began writing Daylight Saving Time after experiencing an unexpected heart attack. It was a wake-up call, bringing clarity to life’s most precious purpose and a realization that there were now fewer years ahead of me than behind. I have always believed that the act of aging was in many ways a privilege and that concept inspired me. In writing the book, my hope was to try to understand the unfolding of a life, to document it in the very moments that it was happening, piece by piece, day by day. To help see it, I chose a period of the year that some call the season of light, the space between the shifting of time, between Standard Time and Daylight Saving. It is a man-made concept, but it is also a remarkable period in the yearly ritual of preserving illumination, the darkest time on our calendars; yet we bravely stretch toward the equinox, toward something brighter, something beyond.

Like aging itself, what ended up in the book were small increments of a path that is nearly unnoticeable—little surprises, unforeseen awakenings, frightening experiences, moments of celebration and resignation, sorrow and delight—mixing like the chemicals of a mad scientist.

The book shares my personal journey, however, the philosophies, ideas and principles introduced are universal. I hope it will resonate with many around the world, no matter the age.

What is one message you would like readers to remember?

I would like readers to see that aging is a privilege, a kind of adventure that should be embraced.

There are many cliches about accepting one’s age: “Age is only a number,” “You're only as old as you feel,” and so on.

Daylight Saving Time is not a book that simply reiterates those old adages. Nor is it a self-help manual. Instead, the book takes it a step further by asking an important question: How do you plan to revel in the final chapters of your life?

Purchasing the Book

Daylight Saving Time: The Power of Growing Older (O-Books/Collective Ink) has received positive reviews from well-known experts, authors, and reviewers around the world. Book Excellence writes, "An authentic and touching memoir that delves into the complexities of aging, offering profound insights and heartfelt reflections on life's journey." In addition, Ryan Lindner, author of The Half-Known Life writes, “A touching, introspective exploration of life as we age…Daylight Saving Time is an exploration of what it means to truly live and grasp the beauty of life before it’s gone.”

The book is available for sale on Amazon, Barnes & Noble, Apple iBooks, Kobo, Nook, Google Play, and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/Daylight-Saving-Time-Power-Growing/dp/1803415118

To connect with David and learn more about his work, visit: www.davidwberner.com. You can also find him on Facebook and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email:Send Email
Country: United States
Website: authornewsnetwork.com

Abdominal Aortic Aneurysm Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies involved by DelveInsight | Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical

Las Vega (Nevada), United States //— As per DelveInsight's assessment, globally, Abdominal Aortic Aneurysm pipeline constitutes key companies continuously working towards developing Abdominal Aortic Aneurysm treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Abdominal Aortic Aneurysm Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Abdominal Aortic Aneurysm Market.

 

The Abdominal Aortic Aneurysm Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Abdominal Aortic Aneurysm Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Abdominal Aortic Aneurysm treatment therapies with a considerable amount of success over the years. Abdominal Aortic Aneurysm Key players such as - Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others, are developing therapies for the Abdominal Aortic Aneurysm treatment 

• Abdominal Aortic Aneurysm Emerging therapies such as - Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others are expected to have a significant impact on the Abdominal Aortic Aneurysm market in the coming years.   

• In January 2024, Arizona-based Nectro Medical has initiated a Phase II/III trial evaluating the safety and efficacy of its endovascular aneurysm stabilisation treatment (Nectero EAST). Nectero EAST is a single-use, endovascular system made up of a dual-balloon delivery catheter and stabiliser mixture of pentagalloyl glucose (PGG). The PGG, when administered locally, can bind to elastin and collagen to potentially strengthen the aortic wall. Animal studies have shown that PGG can hinder the development of abdominal aortic aneurysm (AAA).

 

Abdominal Aortic Aneurysm Overview

Abdominal Aortic Aneurysm (AAA) is a localized enlargement of the abdominal aorta such that the diameter is greater than 3 cm or more than 50% larger than usual. It occurs when atherosclerosis or plaque buildup causes the walls of the abdominal aorta to become weak and bulge outward like a balloon.

 

Get a Free Sample PDF Report to know more about Abdominal Aortic Aneurysm Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/abdominal-aortic-aneurysm-pipeline-insight

 

Abdominal Aortic Aneurysm Pipeline Therapeutics Assessment

• Abdominal Aortic Aneurysm Assessment by Product Type

• Abdominal Aortic Aneurysm By Stage and Product Type

• Abdominal Aortic Aneurysm Assessment by Route of Administration

• Abdominal Aortic Aneurysm By Stage and Route of Administration

• Abdominal Aortic Aneurysm Assessment by Molecule Type

• Abdominal Aortic Aneurysm by Stage and Molecule Type

 

DelveInsight's Abdominal Aortic Aneurysm Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Some of the key companies in the Abdominal Aortic Aneurysm Therapeutics Market include:

Key companies developing therapies for Abdominal Aortic Aneurysm  treatment are - CARDIATIS S.A., CARDINAL HEALTH, INC., COOK MEDICAL, INC., ENDOLOGIX, INC., jotec gmbh, LOMBARD MEDICAL, INC., MEDTRONIC PLC, nano endoluminal sa, TERUMO CORPORATION, W. L. GORE & ASSOCIATES, INC., and others.

 

Download Sample PDF Report to know more about Abdominal Aortic Aneurysm drugs and therapies

 

Emerging Abdominal Aortic Aneurysm Drugs and devices Under Different Phases of Clinical Development Include:

• Metformin Glucophage: Merck Serono

• Ticagrelor: AstraZeneca

• Abdominal Aortic Aneurysm Stent Graft System: Lifetech Scientific

• Fenestrated AlturaTM FEVAR Stent Graft: Lombard Medical

• Seta Latecba Stent Grafts: Latecba SA

• Nectero EAST®: Nectero Medical

• Bifurcated MFM®: Cardiatis

 

Abdominal Aortic Aneurysm Pipeline Analysis:

The Abdominal Aortic Aneurysm pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Abdominal Aortic Aneurysm with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Abdominal Aortic Aneurysm Treatment.

• Abdominal Aortic Aneurysm key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Abdominal Aortic Aneurysm Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Abdominal Aortic Aneurysm market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Abdominal Aortic Aneurysm product details are provided in the report. Download the Abdominal Aortic Aneurysm pipeline report to learn more about the emerging Abdominal Aortic Aneurysm therapies

 

Scope of Abdominal Aortic Aneurysm Pipeline Drug Insight    

• Coverage: Global

• Key Abdominal Aortic Aneurysm Companies: Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others

• Key Abdominal Aortic Aneurysm Therapies: Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others

• Abdominal Aortic Aneurysm Therapeutic Assessment: Abdominal Aortic Aneurysm current marketed and Abdominal Aortic Aneurysm emerging therapies

• Abdominal Aortic Aneurysm Market Dynamics: Abdominal Aortic Aneurysm market drivers and Abdominal Aortic Aneurysm market barriers 

 

Request for Sample PDF Report for Abdominal Aortic Aneurysm Pipeline Assessment and clinical trials

 

Table of Contents

1	Abdominal Aortic Aneurysm Report Introduction
2	Abdominal Aortic Aneurysm Executive Summary
3	Abdominal Aortic Aneurysm Overview
4	Abdominal Aortic Aneurysm- Analytical Perspective In-depth Commercial Assessment
5	Abdominal Aortic Aneurysm Pipeline Therapeutics
6	Abdominal Aortic Aneurysm Late Stage Products (Phase II/III)
7	Abdominal Aortic Aneurysm Mid Stage Products (Phase II)
8	Abdominal Aortic Aneurysm Early Stage Products (Phase I)
9	Abdominal Aortic Aneurysm Preclinical Stage Products
10	Abdominal Aortic Aneurysm Therapeutics Assessment
11	Abdominal Aortic Aneurysm Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Abdominal Aortic Aneurysm Key Companies
14	Abdominal Aortic Aneurysm Key Products
15	Abdominal Aortic Aneurysm Unmet Needs
16	Abdominal Aortic Aneurysm Market Drivers and Barriers
17	Abdominal Aortic Aneurysm Future Perspectives and Conclusion
18	Abdominal Aortic Aneurysm Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma

(Las Vegas, Nevada, United States) As per DelveIns ight's assessment, globally, Alpha Thalassemia pipeline constitutes 4+ key companies continuously working towards developing 5+ Alpha Thalassemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

  

The Alpha Thalassemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

“Alpha Thalassemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha Thalassemia Market. 

 

Some of the key takeaways from the Alpha Thalassemia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Alpha Thalassemia treatment therapies with a considerable amount of success over the years. 

• Alpha Thalassemia companies working in the treatment market are Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others, are developing therapies for the Alpha Thalassemia treatment 

• Emerging Alpha Thalassemia therapies in the different phases of clinical trials are- Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others are expected to have a significant impact on the Alpha Thalassemia market in the coming years.   

• In January 2024, Agios Pharmaceuticals reported positive outcomes in a Phase III ENERGIZE trial of mitapivat for patients with non-transfusion-dependent alpha- or beta-thalassemia, meeting primary and two key secondary endpoints. The company intends to seek regulatory approval for mitapivat as a thalassemia treatment by year-end, incorporating data from the second Phase III ENERGISE-T study (NCT04770779) for adults with transfusion-dependent alpha-thalassemia or beta-thalassemia.

 

Alpha Thalassemia Overview

Alpha thalassemia is a genetic disorder characterized by a deficiency in the production of alpha globin chains, which are essential components of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This deficiency results in a reduced amount of hemoglobin and red blood cells, leading to anemia.

 

Get a Free Sample PDF Report to know more about Alpha Thalassemia Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/alpha-thalassemia-pipeline-insight-pipeline-insight

 

Emerging Alpha Thalassemia Drugs Under Different Phases of Clinical Development Include:

• Etavopivat tablets: Forma Therapeutics, Inc.

• GMCN-508A: Genmedicn Biopharma Ltd.

• Luspatercept: Bristol-Myers Squibb

• Mitapivat: Agios Pharmaceuticals

 

Alpha Thalassemia Route of Administration

Alpha Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical 

 

Alpha Thalassemia Molecule Type

Alpha Thalassemia Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

 

Alpha Thalassemia Pipeline Therapeutics Assessment

• Alpha Thalassemia Assessment by Product Type

• Alpha Thalassemia By Stage and Product Type

• Alpha Thalassemia Assessment by Route of Administration

• Alpha Thalassemia By Stage and Route of Administration

• Alpha Thalassemia Assessment by Molecule Type

• Alpha Thalassemia by Stage and Molecule Type

 

DelveInsight's Alpha Thalassemia Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Alpha Thalassemia product details are provided in the report. Download the Alpha Thalassemia pipeline report to learn more about the emerging Alpha Thalassemia therapies

 

Alpha Thalassemia Pipeline Analysis:

The Alpha Thalassemia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Alpha Thalassemia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha Thalassemia Treatment.

• Alpha Thalassemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Alpha Thalassemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha Thalassemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Alpha Thalassemia drugs and therapies

 

Alpha Thalassemia Pipeline Market Drivers

• Increasing Prevalence genetic disorders and advancement in healthcare technologies, growing demand for treatment for Alpha Thalassemia are some of the important factors that are fueling the Alpha Thalassemia Market.

 

Alpha Thalassemia Pipeline Market Barriers

• However, lack of available appropriate treatments and procedures, high cost of treatment and other factors are creating obstacles in the Alpha Thalassemia Market growth.

 

Scope of Alpha Thalassemia Pipeline Drug Insight    

• Coverage: Global

• Key Alpha Thalassemia Companies: Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others

• Key Alpha Thalassemia Therapies: Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others

• Alpha Thalassemia Therapeutic Assessment: Alpha Thalassemia current marketed and Alpha Thalassemia emerging therapies

• Alpha Thalassemia Market Dynamics: Alpha Thalassemia market drivers and Alpha Thalassemia market barriers 

 

Request for Sample PDF Report for Alpha Thalassemia Pipeline Assessment and clinical trials

 

Table of Contents

1. Alpha Thalassemia Report Introduction

2. Alpha Thalassemia Executive Summary

3. Alpha Thalassemia Overview

4. Alpha Thalassemia- Analytical Perspective In-depth Commercial Assessment

5. Alpha Thalassemia Pipeline Therapeutics

6. Alpha Thalassemia Late Stage Products (Phase II/III)

7. Alpha Thalassemia Mid Stage Products (Phase II)

8. Alpha Thalassemia Early Stage Products (Phase I)

9. Alpha Thalassemia Preclinical Stage Products

10. Alpha Thalassemia Therapeutics Assessment

11. Alpha Thalassemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alpha Thalassemia Key Companies

14. Alpha Thalassemia Key Products

15. Alpha Thalassemia Unmet Needs

16 . Alpha Thalassemia Market Drivers and Barriers

17. Alpha Thalassemia Future Perspectives and Conclusion

18. Alpha Thalassemia Analyst Views

19. Appendix

20. About DelveInsight 

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Monique Lore Stinson Joins Sorghum United as Vice President of Marketing and Media

LINCOLN, NE - September 27, 2024 - Sorghum United is proud to announce the appointment of Monique Lore Stinson as its new Vice President of Marketing and Media, effective immediately. In her new role, Stinson will lead Sorghum United's marketing efforts as the organization scales its impact on the global stage, utilizing her vast experience in media, marketing, and brand development.

Nate Blum, CEO of Sorghum United, expressed his excitement about Stinson joining the team: "I am thrilled for what her unique experience and big brain will bring to our organization as we scale up. Stinson's ability to drive innovation and elevate brand visibility will be a game-changer for us as we continue to grow."

Stinson brings over 25 years of sales, marketing, and media production experience to Sorghum United. A California native, born in Hollywood and raised in West Covina, Stinson was an accomplished athlete at Mt. San Antonio College, excelling in track and field. She is also pursuing her MBA at Pepperdine Graziadio Business School, underscoring her commitment to continued learning and professional development.

Her career is distinguished by leadership roles across industries, including the health and fitness sector, where she notably served as Fitness Manager at 24 Hour Fitness, exceeding sales targets by 118%. Stinson's track record of success is equally matched by her achievements in reality TV production, where she served as casting producer and director for major networks such as MTV, CBS, Fox, ABC, VH1, BET, Lifetime, and Bravo. Her work on Fox’s “Cristina’s Court” earned her two Daytime Emmy Awards, solidifying her reputation as a powerhouse in media production.

Beyond her corporate accomplishments, Stinson is an entrepreneur, having founded several ventures under Moniq, Inc., including CapAquarius Media Co., The Wine Caterers, LLC, and Silicon Beach Coffee Co., to name a few. Her diverse portfolio reflects her entrepreneurial spirit and passion for media, brand placement, and lifestyle ventures.

Stinson’s creative pursuits extend to the literary and film world, where she has several books in progress and recently completed The Pandemic Project—a groundbreaking documentary trilogy that has earned numerous awards at international film festivals. Additionally, she hosts two podcasts on LA Talk Radio and has been accepted into NYU’s prestigious Rolling Stone Journalism program.

Stinson is excited to bring her marketing expertise to Sorghum United and Sorgho Squad. From her home base in Laguna Beach, California, she is ready to amplify the company's national and international presence, with a focus on enhancing brand recognition, visibility, and profitability.

“I’m thrilled to join Sorghum United at such a pivotal time in its growth,” Stinson said. “My passion lies in storytelling, and I can’t wait to help this organization tell its story to the world.”

About Sorghum United

Sorghum United is dedicated to the advancement of the global sorghum industry, fostering research, development, and advocacy for sustainable agricultural practices. The organization promotes awareness, education, and innovation across the sector, connecting sorghum producers, businesses, and consumers worldwide.

Media Contact
Company Name: Sorghum United
Contact Person: Nate Blum
Email:Send Email
Address:2500 West Cardwell Road
City: Lincoln
State: Nebraska
Country: United States
Website: www.sorghumunited.com